METHOD FOR PREDICTION OF RISK OF LUMINAL BREAST CANCER PROGRESSION Russian patent published in 2025 - IPC G01N33/574 C07K16/30 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology, and can be used to predict the risk of progression of luminal breast cancer with diameter of not more than 3 cm. Immunohistochemical analysis of histological preparations prepared from patient’s tumour samples is carried out to determine the number of T-lymphocytes CD8+, number of T-lymphocytes CD4+ and number of M2 macrophages CD163. In cells of the invasive edge of the primary tumour, expression of CD4+, CD8+ and CD163 is determined. If the expression of CD163 is less than 20%, and the sum of the expression of CD4 and CD8 is less than 15%, a low risk of progression is predicted. If CD163 is more than or equal to 20%, and the sum of CD4 and CD8 expression is less than 15%, an average risk of progression is predicted. If CD163 is more than or equal to 20%, and the sum of CD4 and CD8 expression is more than or equal to 15%, a high risk of progression is predicted.

EFFECT: method provides higher prediction accuracy, possibility of predicting a strictly defined molecular subtype of breast cancer at early stages by analysing the indicators of the proposed complex of tumour-associated markers with the assessment of the main subpopulations of infiltrating T-lymphocytes and the level of tumour-infiltrating M2 macrophages.

1 cl, 5 ex